Acies Bio 正在建造一个新的生物制造设施，该设施配备一个 30 立方米的生物反应器，预计于 2026 年第四季度完工，将其发酵能力翻倍至 72 立方米，并提高欧洲生物生产的弹性。 Acies Bio is building a new biomanufacturing facility with a 30 m³ bioreactor, set for completion by Q4 2026, to double its fermentation capacity to 72 m³ and boost Europe’s bioproduction resilience.

Aities Bio正在建造一个新的生物制造设施,有30立方米的生物反应器,定于2026年Q4完成,其发酵能力将增加一倍,达到72立方米,并扩展下游加工。 Acies Bio is building a new biomanufacturing facility with a 30 m³ bioreactor, set for completion by Q4 2026, which will double its fermentation capacity to 72 m³ and expand downstream processing. 该升级支持了该公司的目标,即在整个欧洲提供可扩展的、符合要求的生物技术解决方案,提高将实验室创新转化为商业产品的能力。 The upgrade supports the company’s goal of delivering scalable, compliant biotech solutions across Europe, enhancing its ability to move lab innovations into commercial products. 该项目与欧洲的可持续性和生物经济目标保持一致,加强了区域生物生产复原力。 The project aligns with Europe’s sustainability and bioeconomy goals, bolstering regional bioproduction resilience.